Table of Contents
- Key Points
- Background: Understanding Difficult-to-Control Hypertension
- Study Methods: How the Research Was Conducted
- Key Findings: Detailed Results with All Numbers
- Clinical Implications: What This Means for Patients
- Limitations: What the Study Couldn't Prove
- Recommendations: Actionable Advice for Patients
- Frequently Asked Questions
- Source Information
Key Points
- Baxdrostat reduced systolic blood pressure by up to 15.7 mm Hg at 12 weeks.
- Nearly 40% of patients achieved controlled blood pressure with baxdrostat.
- The medication directly inhibits aldosterone synthase, reducing aldosterone production.
- Both 1 mg and 2 mg doses were effective, with similar results.
- Ongoing treatment is needed to maintain blood pressure reduction.
Background: Understanding Difficult-to-Control Hypertension
Many patients struggle with high blood pressure that remains elevated despite taking multiple medications. This condition, known as uncontrolled or resistant hypertension, affects millions of people worldwide and significantly increases the risk of heart attacks, strokes, and kidney disease.
Research has shown that a hormone called aldosterone plays a key role in driving this difficult-to-treat hypertension. While existing medications called mineralocorticoid receptor antagonists (MRAs) can block aldosterone's effects, they're often underused due to side effects and may actually cause the body to produce more aldosterone over time.
Baxdrostat represents a different approach—it directly inhibits aldosterone synthase, the enzyme that produces aldosterone. Previous smaller studies showed promising results, particularly in patients with resistant hypertension, leading researchers to conduct this larger phase 3 trial to thoroughly evaluate both effectiveness and safety.
Study Methods: How the Research Was Conducted
This was a major international clinical trial conducted at 214 sites across multiple countries. The study followed rigorous scientific standards as a phase 3, double-blind, randomized, placebo-controlled trial—meaning neither patients nor doctors knew who was receiving the actual medication versus placebo.
Researchers enrolled patients who had seated systolic blood pressure between 140 mm Hg and less than 170 mm Hg despite already taking stable doses of either:
- Two antihypertensive medications (for uncontrolled hypertension)
- Three or more medications including a diuretic (for resistant hypertension)
After a 2-week period where all patients received placebo to establish baseline measurements, 796 patients were randomly assigned in equal ratios to three groups:
- 264 patients received 1 mg baxdrostat once daily
- 266 patients received 2 mg baxdrostat once daily
- 264 patients received placebo once daily
All patients continued their existing blood pressure medications throughout the 12-week study period. The research team measured blood pressure at monthly visits using standardized equipment and collected extensive safety data, including regular blood tests to monitor potassium, sodium, kidney function, and drug levels.
Key Findings: Detailed Results with All Numbers
The study produced clear, statistically significant results demonstrating baxdrostat's effectiveness in lowering blood pressure:
At 12 weeks, the average reduction in systolic blood pressure was -14.5 mm Hg (95% CI, -16.5 to -12.5) with 1 mg baxdrostat and -15.7 mm Hg (95% CI, -17.6 to -13.7) with 2 mg baxdrostat, compared to only -5.8 mm Hg (95% CI, -7.9 to -3.8) with placebo.
When compared directly against placebo, the medication produced additional systolic blood pressure reductions of -8.7 mm Hg (95% CI, -11.5 to -5.8) for the 1 mg dose and -9.8 mm Hg (95% CI, -12.6 to -7.0) for the 2 mg dose. Both results were highly statistically significant with p<0.001, meaning there's less than a 0.1% chance these results occurred by random chance.
The study also found impressive results for blood pressure control rates. Nearly 40% of patients receiving baxdrostat achieved controlled blood pressure (below 130 mm Hg systolic) compared to only 18.7% in the placebo group. This represents more than a 2.9-fold increase in the odds of achieving blood pressure control with baxdrostat treatment.
During an 8-week withdrawal period later in the study, patients who were switched from baxdrostat to placebo experienced a blood pressure increase of +1.4 mm Hg, while those continuing baxdrostat maintained an additional -3.7 mm Hg reduction, demonstrating that ongoing treatment is necessary to maintain the benefit.
Clinical Implications: What This Means for Patients
This research represents a significant advancement for patients struggling with difficult-to-control hypertension. The approximately 9 mm Hg additional blood pressure reduction achieved with baxdrostat is clinically meaningful—reductions of this magnitude are associated with approximately 30% reduced risk of stroke and 20% reduced risk of heart disease.
For patients who have not achieved adequate blood pressure control despite multiple medications, baxdrostat may offer a new treatment option that addresses the underlying aldosterone overproduction that drives many cases of resistant hypertension.
The similar effectiveness between 1 mg and 2 mg doses suggests that many patients might achieve good results with the lower dose, potentially minimizing side effects. However, the slightly greater reduction with the higher dose provides flexibility for clinicians to tailor treatment based on individual patient needs and response.
Limitations: What the Study Couldn't Prove
While this study provides strong evidence for baxdrostat's blood pressure-lowering effects, it has several important limitations that patients should understand:
The 12-week duration, while sufficient to establish blood pressure effects, doesn't tell us about long-term safety or whether the benefits are sustained over years of treatment. The ongoing open-label extension phase of the trial will provide additional long-term safety data.
This study focused on blood pressure measurements rather than clinical outcomes like heart attacks or strokes. While blood pressure reduction is known to prevent these events, we can't directly conclude from this study that baxdrostat will reduce cardiovascular events—though it's reasonable to expect it would based on established principles.
The trial excluded certain patient populations, so we don't know how baxdrostat performs in people with very advanced kidney disease, recent cardiovascular events, or other complex medical conditions.
Recommendations: Actionable Advice for Patients
Based on this research, patients with uncontrolled hypertension should:
- Discuss medication options with your doctor if your blood pressure remains elevated despite current treatments
- Ask about aldosterone testing if you have resistant hypertension, as this might help identify if baxdrostat could be appropriate
- Monitor potassium levels regularly if prescribed baxdrostat, as 2.3-3.0% of patients developed elevated potassium compared to 0.4% with placebo
- Continue all current medications unless specifically instructed otherwise by your doctor
Patients should understand that baxdrostat is not yet approved for general use and remains an investigational medication. However, these results suggest it may become an important new option once regulatory reviews are complete.
Frequently Asked Questions
How much does baxdrostat lower blood pressure?
In the phase 3 trial, baxdrostat reduced systolic blood pressure by an average of 14.5 to 15.7 mm Hg at 12 weeks, depending on the dose. Compared to placebo, the additional reduction was about 8.7 to 9.8 mm Hg. This is clinically meaningful and associated with reduced risk of stroke and heart disease.
Why does blood pressure remain high despite multiple medications?
The article explains that a hormone called aldosterone often drives difficult-to-treat hypertension. Existing medications called MRAs can block aldosterone's effects but are underused and may cause the body to produce more aldosterone. Baxdrostat directly inhibits aldosterone synthase, the enzyme that produces aldosterone, offering a new approach.
Is baxdrostat approved for use?
No, baxdrostat is not yet approved for general use. It remains an investigational medication. The phase 3 trial results are promising, but regulatory reviews are still needed. Patients should discuss options with their doctor and continue current medications unless instructed otherwise.
What is baxdrostat and how does it work for high blood pressure?
Baxdrostat is an investigational medication that directly inhibits aldosterone synthase, the enzyme that produces aldosterone. Aldosterone is a hormone that can drive difficult-to-treat hypertension. By blocking its production, baxdrostat helps lower blood pressure in patients who do not respond adequately to multiple existing medications.
Who was eligible to participate in the baxdrostat clinical trial?
The trial enrolled patients with seated systolic blood pressure between 140 and less than 170 mm Hg despite stable doses of either two antihypertensive medications (uncontrolled hypertension) or three or more medications including a diuretic (resistant hypertension). Patients with very advanced kidney disease, recent cardiovascular events, or other complex conditions were excluded.
What were the main side effects of baxdrostat?
The most notable side effect was elevated potassium levels, occurring in 2.3-3.0% of patients taking baxdrostat compared to 0.4% with placebo. Regular blood tests to monitor potassium, sodium, and kidney function were part of the study. Patients prescribed baxdrostat should have potassium levels monitored regularly.
What does a 9 mm Hg reduction in systolic blood pressure mean for health?
A reduction of about 9 mm Hg in systolic blood pressure is clinically meaningful. Reductions of this magnitude are associated with approximately 30% reduced risk of stroke and 20% reduced risk of heart disease. This is based on established principles linking blood pressure reduction to cardiovascular event prevention.
Source Information
Original Article Title: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
Authors: John M. Flack, Michel Azizi, Jenifer M. Brown, Jamie P. Dwyer, Jakub Fronczek, Erika S.W. Jones, Daniel S. Olsson, Shira Perl, Hirotaka Shibata, Ji-Guang Wang, Ulrica Wilderäng, Janet Wittes, and Bryan Williams for the BaxHTN Investigators
Publication: The New England Journal of Medicine (published August 30, 2025)
Clinical Trial Registration: NCT06034743 at ClinicalTrials.gov
Funding: Supported by AstraZeneca and others
This patient-friendly article is based on peer-reviewed research originally published in The New England Journal of Medicine. It preserves all scientific data, statistical findings, and methodological details from the original study while making the information accessible to educated patients.
